
Sign up to save your podcasts
Or


This episode covers CVS's board conducting a strategic review and considering breaking up the company by separating its profitable insurance business from struggling retail pharmacy operations, potentially spinning off Oak Street with Aetna. The episode also discusses Mount Sinai's partnership with Noom's weight loss app for patient referrals, Dana-Farber's new pediatric cancer consortium focused on health equity interventions, FDA ending the shortage designation for Eli Lilly's GLP-1 drug which restricts compounding pharmacies, and a CMS study showing hospital-at-home programs were safe with lower mortality but higher readmissions.
By The Health Management AcademyThis episode covers CVS's board conducting a strategic review and considering breaking up the company by separating its profitable insurance business from struggling retail pharmacy operations, potentially spinning off Oak Street with Aetna. The episode also discusses Mount Sinai's partnership with Noom's weight loss app for patient referrals, Dana-Farber's new pediatric cancer consortium focused on health equity interventions, FDA ending the shortage designation for Eli Lilly's GLP-1 drug which restricts compounding pharmacies, and a CMS study showing hospital-at-home programs were safe with lower mortality but higher readmissions.